Leap Therapeutics to Participate at Piper Sandler 36th Annual Healthcare Conference
Leap Therapeutics to Participate at Piper Sandler 36th Annual Healthcare Conference
A live webcast of the fireside chat may be accessed on the Investors page of the company's website at , where a replay of the events will also be available for a limited time.CAMBRIDGE, Mass., Nov. 26, 2024 /PRNewswire/ -- Leap Therapeutics, Inc. (Nasdaq:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today announced that Douglas E. Onsi, President and Chief Executive Officer, will participate in a fireside chat at the Piper Sandler 36th Annual Healthcare Conference in New York, NY.
馬薩諸塞州劍橋，2024年11月26日 /PRNewswire/ -- leap therapeutics, Inc. (納斯達克：LPTX)，一家專注於開發靶向和免疫腫瘤治療的生物技術公司，今日宣佈，總裁兼首席執行官Douglas E. Onsi將參加在紐約市派傑投資第36屆年度醫療保健大會上的爐邊聊天。
Leap Presentation Details:
Leap演講詳情：
Piper Sandler 36th Annual Healthcare Conference
Date: Wednesday, December 4, 2024
Time: 4:00 p.m. Eastern Time
派傑投資第36屆醫療保健年會
日期：2024年12月4日星期三
時間：東部時間下午4:00
A live webcast of the fireside chat may be accessed on the Investors page of the company's website at , where a replay of the events will also be available for a limited time.
爐邊聊天的直播網絡廣播可以在公司網站的投資者頁面訪問，活動的重播也將在有限時間內提供。
About Leap Therapeutics
Leap Therapeutics (Nasdaq: LPTX) is focused on developing targeted and immuno-oncology therapeutics. Leap's most advanced clinical candidate, DKN-01, is a humanized monoclonal antibody targeting the Dickkopf-1 (DKK1) protein. DKN-01 is being developed in patients with esophagogastric, colorectal, and gynecological cancers. Leap's pipeline also includes FL-501, a humanized monoclonal antibody targeting the growth and differentiation factor 15 (GDF-15) protein, in preclinical development. For more information about Leap Therapeutics, visit or view our public filings with the SEC that are available via EDGAR at http://www.sec.gov or via .
關於Leap Therapeutics
leap therapeutics（納斯達克：LPTX）專注於開發靶向和免疫腫瘤治療。Leap最先進的臨床候選藥物DKN-01是一種人源化單克隆抗體，靶向Dickkopf-1（DKK1）蛋白。DKN-01正在針對食管胃腸道癌、結直腸癌和婦科癌症的患者進行開發。Leap的管線還包括FL-501，這是一種靶向生長和分化因子15（GDF-15）蛋白的人源化單克隆抗體，正在進行臨床前開發。有關leap therapeutics的更多信息，請訪問或查看我們向SEC提交的公共備案文件，這些文件可以通過EDGAR訪問，網址爲http://www.sec.gov或通過其他途徑。
CONTACT:
聯繫人：
Douglas E. Onsi
President & Chief Executive Officer
Leap Therapeutics, Inc.
617-714-0360
[email protected]
Douglas E. Onsi
董事長兼首席執行官
Leap Therapeutics, Inc.
617-714-0360
[email protected]
Matthew DeYoung
Investor Relations
Argot Partners
212-600-1902
[email protected]
Matthew DeYoung
投資者關係
阿哥特合夥人。
212-600-1902
[email protected]
SOURCE Leap Therapeutics, Inc.
來源 leap therapeutics, Inc.
WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?
想要您公司的新聞在PRNEWSWIRE.COM上特色呈現嗎？
譯文內容由第三人軟體翻譯。
